Search

Your search keyword '"Willis, Allison W"' showing total 25 results
Start Over Author "Willis, Allison W" Publisher wiley
25 results on '"Willis, Allison W"'

24. Core concepts in pharmacoepidemiology: Key biases arising in pharmacoepidemiologic studies.

Author

Acton EK, Willis AW, and Hennessy S

Subjects
Humans, Bias, Health Policy, Pharmacoepidemiology methods, Research Design
Abstract

Pharmacoepidemiology has an increasingly important role in informing and improving clinical practice, drug regulation, and health policy. Therefore, unrecognized biases in pharmacoepidemiologic studies can have major implications when study findings are translated to the real world. We propose a simple taxonomy for researchers to use as a starting point when thinking through some of the most pervasive biases in pharmacoepidemiology. We organize this discussion according to biases best assessed with respect to the study population (including confounding by indication, channeling bias, healthy user bias, and protopathic bias), the study design (including prevalent user bias and immortal time bias), and the data source (including misclassification bias and missing data/loss to follow up). This tutorial defines, provides a curated list of recommended references, and illustrates through relevant case examples these key biases to consider when planning, conducting, or evaluating pharmacoepidemiologic studies., (© 2022 John Wiley & Sons Ltd.)

Published
2023
Full Text
View/download PDF

25. Comparing LASSO and random forest models for predicting neurological dysfunction among fluoroquinolone users.

Author

Ellis DE, Hubbard RA, Willis AW, Zuppa AF, Zaoutis TE, and Hennessy S

Subjects
Adult, Cohort Studies, Comorbidity, Humans, Fluoroquinolones adverse effects, Machine Learning
Abstract

Background: Fluoroquinolones are associated with central (CNS) and peripheral (PNS) nervous system symptoms, and predicting the risk of these outcomes may have important clinical implications. Both LASSO and random forest are appealing modeling methods, yet it is not clear which method performs better for clinical risk prediction., Purpose: To compare models developed using LASSO versus random forest for predicting neurological dysfunction among fluoroquinolone users., Methods: We developed and validated risk prediction models using claims data from a commercially insured population. The study cohort included adults dispensed an oral fluoroquinolone, and outcomes were CNS and PNS dysfunction. Model predictors included demographic variables, comorbidities and medications known to be associated with neurological symptoms, and several healthcare utilization predictors. We assessed the accuracy and calibration of these models using measures including AUC, calibration curves, and Brier scores., Results: The underlying cohort contained 16 533 (1.18%) individuals with CNS dysfunction and 46 995 (3.34%) individuals with PNS dysfunction during 120 days of follow-up. For CNS dysfunction, LASSO had an AUC of 0.81 (95% CI: 0.80, 0.82), while random forest had an AUC of 0.80 (95% CI: 0.80, 0.81). For PNS dysfunction, LASSO had an AUC of 0.75 (95% CI: 0.74, 0.76) versus an AUC of 0.73 (95% CI: 0.73, 0.74) for random forest. Both LASSO models had better calibration, with Brier scores 0.17 (LASSO) versus 0.20 (random forest) for CNS dysfunction and 0.20 (LASSO) versus 0.25 (random forest) for PNS dysfunction., Conclusions: LASSO outperformed random forest in predicting CNS and PNS dysfunction among fluoroquinolone users, and should be considered for modeling when the cohort is modest in size, when the number of model predictors is modest, and when predictors are primarily binary., (© 2021 John Wiley & Sons Ltd.)

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results